Similar articles for PMID: 11345975

Year	Number of Results
1898	1
1908	1
1931	1
1935	1
1937	1
1961	1
1965	1
1967	3
1968	2
1970	1
1971	1
1972	2
1973	2
1977	1
1978	1
1980	2
1981	6
1982	1
1983	2
1985	1
1986	3
1987	5
1989	4
1990	4
1991	7
1992	2
1993	4
1994	7
1995	2
1996	5
1997	10
1998	8
1999	9
2000	13
2001	9
2002	4
2003	10
2004	13
2005	10
2006	22
2007	13
2008	17
2009	14
2010	8
2011	23
2012	15
2013	22
2014	15
2015	15
2016	8
2017	5
2018	8
2019	12
2020	12
2021	1

1

American Academy of Pediatrics. Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mumps-rubella vaccine.

American Academy of Pediatrics. Committee on Infectious Diseases. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics. 1998 Jan;101(1 Pt 1):129-33. Pediatrics. 1998. PMID: 11345975

2

Progress toward implementation of a second-dose measles immunization requirement for all schoolchildren in the United States.

Kolasa MS, Klemperer-Johnson S, Papania MJ. Kolasa MS, et al. J Infect Dis. 2004 May 1;189 Suppl 1:S98-103. doi: 10.1086/374720. J Infect Dis. 2004. PMID: 15106097

3

Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.

LeBaron CW, Bi D, Sullivan BJ, Beck C, Gargiullo P. LeBaron CW, et al. Pediatrics. 2006 Oct;118(4):1422-30. doi: 10.1542/peds.2006-0678. Pediatrics. 2006. PMID: 17015532

4

Measles vaccination: revised recommendations for immunization.

Reece SM. Reece SM. Nurse Pract. 1990 Dec;15(12):19-20, 23-4. Nurse Pract. 1990. PMID: 2284058

5

Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).

McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS; Centers for Disease Control and Prevention. McLean HQ, et al. MMWR Recomm Rep. 2013 Jun 14;62(RR-04):1-34. MMWR Recomm Rep. 2013. PMID: 23760231 Free article.

6

Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.

Vesikari T, Baer M, Willems P. Vesikari T, et al. Pediatr Infect Dis J. 2007 Feb;26(2):153-8. doi: 10.1097/01.inf.0000250689.09396.21. Pediatr Infect Dis J. 2007. PMID: 17259879 Clinical Trial.

7

The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.

Bart KJ, Orenstein WA, Hinman AR. Bart KJ, et al. Dev Biol Stand. 1986;65:45-52. Dev Biol Stand. 1986. PMID: 3104117 Review.

8

Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?

Abbassy AA, Barakat SS, Abd El Fattah MM, Said ZN, El Metwally HA. Abbassy AA, et al. East Mediterr Health J. 2009 Jan-Feb;15(1):85-93. East Mediterr Health J. 2009. PMID: 19469430 Free article.

9

A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.

Jaber SM. Jaber SM. Saudi Med J. 2006 Jan;27(1):63-9. Saudi Med J. 2006. PMID: 16432596

10

Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Watson JC, et al. MMWR Recomm Rep. 1998 May 22;47(RR-8):1-57. MMWR Recomm Rep. 1998. PMID: 9639369 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed